GSK Satellite symposium
Elevating standard of care in MM: unlocking the potential of novel BCMA combinations
May 13, 2022
13:00 – 14:15 CEST
Virtual and live in Paris, France
Chair:
Antonio Palumbo, MD
Zug, Switzerland
Global Medical Expert Hematology, GSK
Speakers:
Meletios Dimopoulos, MD
Athens, Greece
University of Athens School of Medicine
Paul Richardson, MD
Boston, USA
Dana-Farber Cancer Institute
Evangelos Terpos, MD, PhD
Athens, Greece
University of Athens School of Medicine
Suzanne Trudel, MD, MSc
Toronto, Canada
Princess Margaret Cancer Centre
OBJECTIVES:
- Understand the changing landscape associated with MM
- Review efficacy and safety of established agents in combination with novel treatments in early RRMM
- Discuss important factors (eg, age, fitness level, patient refractoriness, prior toxicity exposure, MRD negativity, risk status, QOL) that should be considered to help differentiate available regimens
- Debate the approach to sequencing the next regimen at first relapse
AGENDA:
| 10 min | Welcome and short introduction Antonio Palumbo, MD |
| 15 min | Exploring the evolving landscape in MM Paul Richardson, MD |
| 15 min | Adopting new approaches in early RRMM: Integrating BCMA combinations Suzanne Trudel, MD, MSc |
| 15 min | Moving towards optimized benefit-risk with BCMA-targeted agents in early MM Meletios Dimopoulos, MD |
| 10 min | Roundtable discussion: approach to sequencing the next regimen at first relapse Paul Richardson, MD, Evangelos Terpos, MD, PhD, Suzanne Trudel, MD, MSc; facilitated by Antonio Palumbo, MD |
| 5 min | Q&A Paul Richardson, MD, Evangelos Terpos, MD, PhD, Suzanne Trudel, MD, MSc; facilitated by Antonio Palumbo, MD |
| 5 min | Closing remarks Antonio Palumbo, MD |
